GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TWi Biotechnology Inc (ROCO:6610) » Definitions » Debt-to-EBITDA

TWi Biotechnology (ROCO:6610) Debt-to-EBITDA : -0.03 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is TWi Biotechnology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

TWi Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$2.37 Mil. TWi Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$5.60 Mil. TWi Biotechnology's annualized EBITDA for the quarter that ended in Dec. 2023 was NT$-250.25 Mil. TWi Biotechnology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for TWi Biotechnology's Debt-to-EBITDA or its related term are showing as below:

ROCO:6610' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.22   Med: -0.05   Max: -0.03
Current: -0.05

During the past 11 years, the highest Debt-to-EBITDA Ratio of TWi Biotechnology was -0.03. The lowest was -1.22. And the median was -0.05.

ROCO:6610's Debt-to-EBITDA is ranked worse than
100% of 273 companies
in the Biotechnology industry
Industry Median: 1.3 vs ROCO:6610: -0.05

TWi Biotechnology Debt-to-EBITDA Historical Data

The historical data trend for TWi Biotechnology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TWi Biotechnology Debt-to-EBITDA Chart

TWi Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.08 -1.22 -0.04 -0.05

TWi Biotechnology Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.06 -0.04 -0.02 -0.03

Competitive Comparison of TWi Biotechnology's Debt-to-EBITDA

For the Biotechnology subindustry, TWi Biotechnology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TWi Biotechnology's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TWi Biotechnology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where TWi Biotechnology's Debt-to-EBITDA falls into.



TWi Biotechnology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

TWi Biotechnology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.368 + 5.603) / -160.857
=-0.05

TWi Biotechnology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.368 + 5.603) / -250.254
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


TWi Biotechnology  (ROCO:6610) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


TWi Biotechnology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of TWi Biotechnology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


TWi Biotechnology (ROCO:6610) Business Description

Traded in Other Exchanges
N/A
Address
Lane 221, Kang Chien Road, 8th Floor, Number 41, Neihu District, Taipei, TWN, 11494
TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.

TWi Biotechnology (ROCO:6610) Headlines

No Headlines